Skip to main content

Biological E gets WHO nod for JnJ COVID vaccine production


Clinical courses

Biological E gets WHO nod for JnJ COVID vaccine production

Biological E gets the World Health Organisation (WHO) approval to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.

The Johnson & Johnson COVID-19 vaccine consists of a replication-incompetent recombinant adenovirus type 26 (Ad26) viral vector expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in a stabilized conformation.

The US embassy in India said in a tweet on 22 june, "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing."

Apart from that, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 year. It is India's first indigenously developed RBD protein subunit vaccine.

The Drugs Controller General of India (DCGI) recently approved Corbevax as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination (two doses) of COVAXIN or COVISHIELD vaccines for restricted use in emergency situation.

Biological E  supplies its vaccines to more than 130 countries and its therapeutic products are sold in India and the USA, Europe.  Biological E currently has 8 WHO-prequalified vaccines in its portfolio and 5 USFDA approved Injectables.

Subscribe to PharmaTutor News Alerts by Email

<< Back to Pharma News